Liu Y, Hashizume K, Chen Z, Samoto K, Ningaraj N, Asotra K, Black K L
Maxine Dunitz Neurosurgical Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Neurol Res. 2001 Jun;23(4):379-87. doi: 10.1179/016164101101198596.
Localization of B2 receptors in brain tumor cells and microvessel endothelial cells of the brain tumors was investigated to study the differential sensitivity of brain tumors to bradykinin. The present study shows that B2 receptor expression levels vary in cultured RG2, C6 and 9L glioma cells as well as in the intracerebral tumors established with these cell lines in rats. The double immunohistochemical data indicate that B2 receptors are localized to tumor cells and not to the tumor capillaries. Immunostaining and Western blot analysis for B2 receptor showed that the B2 receptor expression was in the order C6 > RG2 > 9L. The permeability studies on RG2, C6 and 9L tumors in rats showed that C6 tumor had the highest increase (178%) in Ki (unidirectional transport across blood-brain barrier (BBB)/blood-tumor barrier (BTB)), while 9L tumor had the least increase of Ki (35%) over the control group, following intracarotid infusion of bradykinin. We found a positive correlation (r = 0.965, p < 0.001) between B2 receptor levels and bradykinin-induced increase in BTB permeability. We conclude that B2 receptors are localized to tumor cells and not to normal or tumor capillary endothelial cells. C6 tumor with highest B2 receptor expression was most responsive to bradykinin, while RG2 and 9L tumors with lower B2 receptor expression level were less sensitive to bradykinin with regard to BTB permeability.
为研究脑肿瘤对缓激肽的不同敏感性,对脑肿瘤细胞及脑肿瘤微血管内皮细胞中B2受体的定位进行了研究。本研究表明,在培养的RG2、C6和9L胶质瘤细胞以及用这些细胞系在大鼠体内建立的脑内肿瘤中,B2受体表达水平各不相同。双重免疫组化数据表明,B2受体定位于肿瘤细胞而非肿瘤毛细血管。对B2受体的免疫染色和蛋白质印迹分析显示,B2受体表达顺序为C6 > RG2 > 9L。对大鼠RG2、C6和9L肿瘤的通透性研究表明,在颈内动脉注入缓激肽后,C6肿瘤的Ki(跨血脑屏障(BBB)/血肿瘤屏障(BTB)的单向转运)增加最高(178%),而9L肿瘤的Ki增加最少(35%),相对于对照组。我们发现B2受体水平与缓激肽诱导的BTB通透性增加之间存在正相关(r = 0.965,p < 0.001)。我们得出结论,B2受体定位于肿瘤细胞而非正常或肿瘤毛细血管内皮细胞。B2受体表达最高的C6肿瘤对缓激肽反应最敏感,而B2受体表达水平较低的RG2和9L肿瘤在BTB通透性方面对缓激肽较不敏感。